Ironwood Pharmaceuticals, Inc. (IRWD)
4.41
+0.14
(+3.28%)
USD |
NASDAQ |
Sep 02, 16:00
4.40
-0.01
(-0.23%)
After-Hours: 20:00
Ironwood Pharmaceuticals Research and Development Expense (TTM) : 86.86M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 86.86M |
| March 31, 2026 | 87.80M |
| December 31, 2025 | 93.26M |
| September 30, 2025 | 96.76M |
| June 30, 2025 | 104.08M |
| March 31, 2025 | 111.06M |
| December 31, 2024 | 109.41M |
| September 30, 2024 | 119.57M |
| June 30, 2024 | 122.53M |
| March 31, 2024 | 126.95M |
| December 31, 2023 | 114.21M |
| September 30, 2023 | 89.25M |
| June 30, 2023 | 68.16M |
| March 31, 2023 | 44.94M |
| December 31, 2022 | 42.85M |
| September 30, 2022 | 64.23M |
| June 30, 2022 | 63.60M |
| March 31, 2022 | 64.28M |
| December 31, 2021 | 68.88M |
| September 30, 2021 | 53.24M |
| June 30, 2021 | 62.56M |
| March 31, 2021 | 72.23M |
| December 31, 2020 | 84.50M |
| September 30, 2020 | 94.32M |
| June 30, 2020 | 98.83M |
| Date | Value |
|---|---|
| March 31, 2020 | 106.15M |
| December 31, 2019 | 110.32M |
| September 30, 2019 | 112.19M |
| June 30, 2019 | 116.00M |
| March 31, 2019 | 110.42M |
| December 31, 2018 | 115.42M |
| September 30, 2018 | 127.99M |
| June 30, 2018 | 136.87M |
| March 31, 2018 | 151.03M |
| December 31, 2017 | 148.23M |
| September 30, 2017 | 143.79M |
| June 30, 2017 | 144.25M |
| March 31, 2017 | 138.59M |
| December 31, 2016 | 136.73M |
| September 30, 2016 | 128.68M |
| June 30, 2016 | 116.98M |
| March 31, 2016 | 113.95M |
| December 31, 2015 | 108.75M |
| September 30, 2015 | 108.60M |
| June 30, 2015 | 107.89M |
| March 31, 2015 | 101.39M |
| December 31, 2014 | 98.76M |
| September 30, 2014 | 90.71M |
| June 30, 2014 | 85.53M |
| March 31, 2014 | 84.69M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Rigel Pharmaceuticals, Inc. | 43.68M |
| AbbVie, Inc. | 9.714B |
| Marker Therapeutics, Inc. | 8.806M |
| Theriva Biologics, Inc. | 5.306M |
| Fortress Biotech, Inc. | 1.186M |